Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 7Myelodysplastic Syndromes 2Leukemia 2Sarcoma, Myeloid 1Recurrence 1Myeloproliferative Disorders 1Leukemia, Myelomonocytic, Chronic 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 17Cytarabine 11venetoclax 9fludarabine 9Mycophenolic Acid 8Busulfan 7fludarabine phosphate 6Whole-Body Irradiation 6ruxolitinib 5Tacrolimus 5Methotrexate 5Daunorubicin 5Cyclosporine 5Azacitidine 5ponatinib 4Vincristine 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Etoposide 4Dexamethasone 4blinatumomab 3asciminib 3Prednisone 3Mercaptopurine 3Inotuzumab Ozogamicin 3Doxorubicin 3revumenib 2quizartinib 2pegfilgrastim 2pegaspargase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia × quizartinib × 90 days × Clear all
NCT06578247 2026-04-30

QuANTUM-WILD

Daiichi Sankyo

Phase 3 Recruiting
700 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Kura Oncology, Inc.

Phase 1 Recruiting
420 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡